Zydus Cadila receives final approval from USFDA for Oxybutynin Chloride Extended-Release Tablets

28 Jun 2017 Evaluate

Zydus Cadila has received the final approval from the USFDA to market Oxybutynin Chloride Extended-Release Tablets in the strengths of 5 mg, 10 mg, and 15 mg. The drug is used to treat symptoms of overactive bladder and urinary incontinence (urine leakage) and will be produced at the group's formulation manufacturing facility at Moraiya in Ahmedabad. The estimated sale for Oxybutynin Chloride Extended-Release Tablets is $150.9 million.

The group now has more than 120 approvals and has so far filed over 300 ANDAs, since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences Share Price

911.00 1.00 (0.11%)
17-Feb-2026 10:38 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1713.80
Dr. Reddys Lab 1265.80
Cipla 1346.20
Zydus Lifesciences 911.00
Lupin 2247.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×